About Us
CUREator is Australia’s leading life sciences incubator delivered by the Brandon BioCatalyst, a collaboration of 50 + of Australia and New Zealand’s leading Medical Research Institutes.  It is designed to accelerate the translation and commercialisation of early-stage Australian health and medical research, bridging the gap between discovery and investment readiness.

Our aim is to transform promising biomedical research opportunities into clinical and market-ready solutions that benefit patients, provide a return on national research investment, and grow the Australian biotech ecosystem.

We provide non-dilutive grant funding, hands-on support and access to global networks to new biotech spinouts emerging from academic research and small to medium-sized biotech enterprises with commercial potential.

CUREator adopts the established review processes of the Brandon BioCatalyst investment model, ensuring thorough due diligence, expert advice, and independent investment insights. Our incubator model helps companies achieve key technical and commercial milestones to secure follow-on investments or partnerships.

Team
Delivered by a dedicated team, we partner with promising Australian biotech innovations, providing them with the funding and support they need to succeed and grow the Australian biotech industry.

Amanda is a Clinical Scientist with expertise in commercialisation and a PhD in Developmental Biology.

Amanda Vrselja

Program Head

Patricia is skilled in translational project management
advancing drug discovery projects across various therapeutic areas.

Patricia Rueda

Analyst

Aaron has a PhD in Medicinal Chemistry and experience in drug discovery and commercialisation.

Aaron De Bono

Analyst

Christina has extensive experience in drug discovery
project leadership
and commercialisation in biotechnology and research.

Christina Kulis

Analyst

Opportunity
Australia boasts world-leading medical research and clinical capabilities, supported by significant government funding. However, many groundbreaking innovations lack the initial financial support and expertise to become ‘investment-ready’ opportunities.

Early funding pathways and expert assistance are crucial to bridging this gap and growing the Australian biotech ecosystem.

CUREator addresses this gap by combining early-stage funding, expert guidance, and investor discipline to accelerate translation. Leveraging Brandon BioCatalyst’s experience in managing the development, translation, and commercialisation of biomedical discoveries, CUREator ensures projects benefit from thorough technical and commercial due diligence, expert advice, and independent investment insights.